CHIMERIC THERAPEUTICS

CHIMERIC

PIONEERS IN CELL THERAPY

Investor Update | July 2024



ASX:
CHM

2024

CHIMERICTHERAPEUTICS.COM

DISCLAIMER

Certain statements contained in this presentation, including, without limitation, statements containing the words "believes," "plans," "expects," "anticipates," and words of similar import, constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Chimeric (collectively, "Chimeric" or the "Company") to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favourable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products.

Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law.

This presentation may not contain all the details and information necessary for you to make a decision or evaluation. Neither this presentation nor any of its contents may be used for any other purpose without the prior written consent of the Company.

CHIMERIC THERAPEUTICS

20
24

ASX:CHM

CHM is a cancer cell therapy company with 3 CAR T & NK assets in 4 Phase 1/1b trials

CHIMERIC THERAPEUTICS

20
24

INVESTMENT HIGHLIGHTS

- **4 phase 1/1b clinical trials**
  under 3 FDA INDs at 4 leading US centres
- **Multiple clinical updates**
  in the next 12mths
- **Experienced leadership team**
  in cell therapy clinical development
- CHM-CDH17
  the ONLY CDH17 CAR-T in clinical trials
- **First in class**
  CLTX-CAR for brain cancer
- **Robust and long life**
  patent portfolio

CORPORATE PROFILE

Exchange	**ASX:CHM**
Share Price	**$0.02**
52 Week Range	**$0.018- 0.047**
Market Cap	**~$16M**
Shares on issue	**841M**

IPO 2022

Capital Raised since IPO	**$69M**
Major Shareholder: Paul Hopper	**11.1%**

CHIMERIC THERAPEUTICS

CAR-T CELL THERAPY EXPLAINED

Use a patients own blood cells to make their individualised cancer therapy



Leukapheresis (blood draw) from individual patient

Infusion into individual patient

Cell Therapy has been used for over 10 years in patients globally, with great success

Emily Whitehead more than a decade after first CAR-T treatment for blood cancer

CHM: BROAD PORTFOLIO

3 Novel cell therapies; 4 Clinical Trials

CHM CDH17

CAR-T

Technology from:

Penn
University of Pennsylvania

PHASE 1/2 TRIAL OPEN

Sarah Cannon Cancer Centre

CHM CLTX

CAR-T

Technology from:

City of Hope

Phase 1 completed: COH

PHASE 1B TRIAL OPEN

Sarah Cannon Cancer Centre

CHM CORE-NK

'OFF THE SHELF' NK

Technology from:

CASE WESTERN RESERVE UNIVERSITY

PHASE 1B TRIAL OPEN

MD Anderson

PHASE 1B TRIAL OPEN

Case Western

CHIMERIC THERAPEUTICS

THE ONLY CDH17 CAR-T GLOBALLY IN CLINICAL TRIALS

2024

CHIMERIC THERAPEUTICS

CDH17 OVERVIEW

- **CDH17 is protein on the surface of Gastrointestinal cancers** (green on purple cells in picture)
- Compelling pre-clinical efficacy in Gastric, Pancreatic and Neuroendocrine cancers
- Pre-clinical models indicate no toxicity on healthy cells
- This is the first CDH17 CAR T cell therapy in clinical trials in the world
- Over a Decade of Development at the world-renowned cell therapy centre, the University of Pennsylvania


Dr. Xianxin Hua, M.D., Ph.D.


Dr. Carl June M.D.



INTENSE SCIENTIFIC INTEREST IN CDH17

200+ PUBLICATIONS IN PAST 2 YEARS

'24

Biomater Res.
2024 Jun; 0041 (28)

Cadherin 17 Nanobody-Mediated Near-Infrared-II Fluorescence Imaging-Guided Surgery and Immunotoxin Delivery for Colorectal Cancer



'24

Molecular & Cellular Proteomics
2024 May; 100766 (23)

Proteomics-Derived Biomarker Panel Facilitates Distinguishing Primary Lung Adenocarcinomas With Intestinal or Mucinous Differentiation From Lung Metastatic Colorectal Cancer

'24

Cancer Res.
2024 March 15; 3131 (84)

Novel CDH17-targeting antibody-drug conjugate exhibits anti-tumor efficacy in preclinical models of gastrointestinal cancers

'24

Cancer Res.
2024 March 15; 1900 (84)

TORL-3-600, a novel antibody drug conjugate directed against cadherin 17 (CDH17), has preclinical efficacy in colorectal, gastric, and pancreatic cancer



'24

Cancer Cell Int.
2024 Feb; 67 (24)

Targeted drug delivery using nanobodies to deliver efective molecules to breast cancer cells: the most attractive application of nanobodies



'24

J Exp Clin Cancer Res.
2024 Jan 24; 31(43)

A complex of cadherin 17 with desmocollin 1 and p120-catenin regulates colorectal cancer migration and invasion according to the cell phenotype



'23

Lung.
2023 Oct; 489-97(201)

Targeting CDH17 with Chimeric Antigen Receptor-Redirected T Cells in Small Cell Lung Cancer



'23

Front. Pharmacol.
2023 Sep; 1189799 (14)

Novel biomarkers used for early diagnosis and tyrosine kinase inhibitors as targeted therapies in colorectal cancer

'23

JCO Glob Oncol.
2023 Aug; 25 (9)

Phase 1A, first-in-human study of ARB202, bispecific antibody to CDH17 and CD3, in advanced gastrointestinal malignancies expressing CDH17

'23

JCO.
2023 Jun; e14539 (41)

Development of allogenic nonviral RNA-based CAR-NK therapy targeting CDH17 in relapsed/ refractory gastrointestinal cancer



'23

Sci Rep.
2023 Apr; 6493 (13)

Molecular mechanism underlying the increased risk of colorectal cancer metastasis caused by single nucleotide polymorphisms in LI-cadherin gene

'23

JCO.
2023 Feb; TPS820 (41)

A phase Ia/Ib, open-label, dose escalation study of the TRAILR2 agonist BI 905711 in combination with chemotherapy (CT) in patients (pts) with advanced GI cancers

'23

JCO.
2023 Feb; 115 (41)

A phase Ia/b first-in-human, open-label, multicenter study of BI 905711, a bispecific TRAILR2 agonist, in patients with advanced gastrointestinal cancers



'23

Cancers.
2023 Feb; 1171 (15)

CAR-Based Immunotherapy of Solid Tumours—A Survey of the Emerging Targets

'23

Cancers.
2023 Jan; 158 (15)

Integrative Clinical and DNA Methylation Analyses in a Population-Based Cohort Identifies CDH17 and LRP2 as Risk Recurrence Factors in Stage II Colon Cancer

'22

Nat Cancer.
2022 May; (3)

CDH17-directed CAR T cells for solid tumors

CHM CDH17 IS THE FIRST CDH17 TARGETING CAR-T IN CLINICAL TRIALS

COMPANY	CHIMERIC THERAPEUTICS	ARBELE	TORL BIOTHERAPEUTICS	Boehringer Ingelheim
ASSET	CHM-CDH17[1]	Cabomatig[2,8]	TORL-3-600[3,6]	BI 905711[4,5,7]
PHASE	Phase 1/2	Phase 1	Phase 1	Phase 1
MODE	CAR-T	Antibody	Antibody	Antibody
INDICATIONS	Solid tumors (NET; CRC; GC)[1]	Solid tumors (Cholangio.; Liver cancer; CRC.; Panc.; G/GEJC; Eso.)[2]	Solid tumors (CRC)[3]	Solid tumors (CRC; GC; Eso.; Pan.; Cholangio.; GBC; SIA)[4,5]

References: 1. CHM-2101 trial; 2. Cabomatig trial; 3. TORL-3-600 trial; 4. BI 905711 trial1; 5. BI 905711 trial2; 6. TORL PR; 7. BI 905711 ASCO GI'23 Results; 8. Arbele Pipeline

CHM CDH17 CAR-T PHASE 1 RECRUITING

The first CDH17 CAR T cell therapy in clinical trials in the world.

CHM CDH17

CAR-T

Technology from:

Penn
University of Pennsylvania

PHASE 1/2 TRIAL OPEN

Sarah Cannon Cancer Centre

PERSONALISED CAR-T: AUTOLOGOUS

First in class CDH17 CAR T for gastrointestinal cancers

FDA IND clearance: **Nov 23**

Manufacturing: **GMP Ready**

Phase 1/2 Trial Open in Colorectal, Gastric and Neuroendocrine Cancers

N= 15 patients

CHIMERIC THERAPEUTICS

20
24

ENCOURAGING PRE-CLINICAL RESULTS

CDH17 CAR T induced complete eradication of tumours with no relapse in seven mouse models



NEUROENDOCRINE TUMOURS



GASTRIC CANCER



PANCREATIC CANCER



CHM CDH17

CAR-T

Penn
University of Pennsylvania

CHM CDH17 CLINICAL DEVELOPMENT STRATEGY

FDA IND approved phase 1/2 | Clinicaltrials.gov Identifier NCT 06055439

JUNE '25

PHASE 1 SAFETY | **PHASE 2 EFFICACY** | **REGISTRATION**

N=15

MARKET UPDATE 3/3 + 5/5

N=70

Partner or License to Big Pharma

SCRI Sarah Cannon Research Institute

Penn University of Pennsylvania

The University of Texas MD Anderson Cancer Center

UChicagoMedicine Comprehensive Cancer Center

CHM CDH17

CAR-T

CHIMERIC THERAPEUTICS

CHM CDH17
TOTAL GLOBAL MARKET SIZE



CHM CDH17
CAR-T

https://www.grandviewresearch.com/industry-analysis/pancreatic-cancer-treatment-market
https://www.grandviewresearch.com/industry-analysis/stomach-cancer-gastric-cancer-market
https://www.grandviewresearch.com/industry-analysis/colorectal-cancer-crc-drugs-therapeutic-market

CHIMERIC THERAPEUTICS

20
24

CHLOROTOXIN (CLTX) CAR T OVERVIEW

Designed by the team at City of Hope to target **glioblastoma**, one of the most lethal types of brain cancer.

Uniquely uses **Chlorotoxin**, a peptide derived from deathstalker scorpion venom to target brain cancer.

Phase 1a clinical trial completed at City of Hope showed **early and encouraging signs.**

CHM holds a global exclusive license to CLTX CAR T.

CLTX CAR T has a long life, intellectual property profile expiring 2036.

Deathstalker
(Leiurus quinquestriatus)



Brain cancer
under the microscope

CHIMERIC THERAPEUTICS

CHM CDH17 CAR-T PHASE 1 RECRUITING

The first CLTX CAR T cell therapy in development in the world

CHM CLTX

CAR-T

Technology from:

City of Hope

Phase 1 completed: COH

PHASE 1B TRIAL OPEN

Sarah Cannon Cancer Centre

PERSONALISED CAR-T: AUTOLOGOUS

First in class CLTX CAR T for brain cancer and solid tumours

Preliminary **Positive Phase 1A Clinical Trial** in Relapse/ Recurrent Glioblastoma

Ongoing Phase 1B Clinical Trial in **Recurrent Glioblastoma**

Revising Phase 1b Clinical design

Manufacturing: **GMP ready**

CHM CLTX CLINICAL DEVELOPMENT STRATEGY

FDA IND approved phase 1B

CHM CLTX
CHM 1101

CHIMERIC THERAPEUTICS

20
24

CHM CLTX
CHM 1101
TOTAL GLOBAL MARKET SIZE

https://www.grandviewresearch.com/industry-analysis/glioblastoma-multiforme-treatment-gbm-market

CHM CLTX
CHM 1101

CHIMERIC THERAPEUTICS

OFF THE SHELF (ALLO)



CHIMERIC THERAPEUTICS

NK CELL THERAPY OVERVIEW

Natural killer cells (NK) are white blood cells that can destroy cancer cells and other infections in the body & are a critical part of the immune system

- Can identify and kill cancer cells
- Low risk of safety concerns
- They constantly patrol the body to eradicate infections
- They grow in bone marrow

OFF THE SHELF
ALLOGENEIC

nature

Membrane bound IL-21 based NK cell feeder cells drive robust expansion and metabolic activation of NK cells

Evelyn O. Ojo, Ashish Arunkumar Sharma, Ruifu Liu, Stephen Moreton, Mary-Ann Checkley-Luttge, Kalpana Gupta, Grace Lee, Dean A. Lee, Folashade Otegbeye, Rafick-Pierre Sekaly, Marcos de Lima & David N. Wald



CORE NK CELLS

CHIMERIC THERAPEUTICS

CHM CORE-NK PHASE 1 RECRUITING

Two Phase 1 trials recruiting

CHM CORE-NK

'OFF THE SHELF' NK

Technology from:

CASE WESTERN RESERVE UNIVERSITY

PHASE 1B TRIAL OPEN	PHASE 1B TRIAL OPEN
MD Anderson	Case Western

CORE-NK: ALLOGENEIC

Source of cells: Universal Healthy Donor

Positive Phase 1A Clinical Trial completed at Case Western

Two ongoing Phase 1B Clinical Trials in AML and CRC

AML: Cohort 1 deemed safe and moved to Cohort 2

Opportunity to combine with other technologies

CHM CORE NK PHASE 1 STUDY RESULTS

Ongoing Complete response

PATIENT #8
33-year-old female

DIAGNOSIS: Ovarian cancer

HISTORY: Progressive disease with prior allogeneic transplant

SAFETY: No dose limiting toxicities, no cytokine release syndrome, no GvHD

CHIMERIC THERAPEUTICS

20
24

AML PHASE 1B CLINICAL TRIAL OPEN

CHM CORE-NK + AZA + VEN in front-line AML

Clinical Trials.gov Identifier: **NCT05834244**

THE UNIVERSITY OF TEXAS
MD Anderson Cancer Center



CORE NK CELLS

FDA REGISTERED CHEMOTHERAPY

FDA REGISTERED BLOOD CANCER DRUG

CHM CORE NK

'OFF THE SHELF' NK

CHIMERIC THERAPEUTICS

CRC PHASE 1B CLINICAL TRIAL OPEN

WORLD FIRST TRIAL OF NK CELLS WITH VACTOSERTIB IN BOWEL CANCER

CLINICAL TRIALS.GOV IDENTIFIER: **NCT05400122**

CASE WESTERN RESERVE UNIVERSITY



CORE NK CELLS



VACTOSERTIB

A clinical drug candidate that inhibits TGF- β signalling, a pathway known to inhibit the effect of immunotherapy

Building upon the efficacy signal in the phase 1A CORE NK clinical trial, this trial aims to improve disease responses in patients through the coadministration of Vactosertib with CORE NK cells

CHM CORE NK

'OFF THE SHELF' NK

CHM CORE-NK CLINICAL DEVELOPMENT STRATEGY

X 2 FDA IND approved phase 1B



CHM CORE NK

'OFF THE SHELF' NK

MULTIPLE VALUE REALISATION PATHWAYS

Sale of the Company

Develop Independently

Strategic Partnership with Big Pharma

MULTIPLE CLINICAL CATALYSTS IN THE NEXT 12MTHS

2023 Achievements and Deliverables in 2024

	2023 Achievements	2024 Deliverables
CHM CDH17 CHM 2101	✓ FDA IND Clearance for Ph. 1/2 Trial	✓ Ph. 1/2 Site Open • 1st patient dosed • Ph. 1 Preliminary Data
CHM CLTX CHM 1101	✓ Ph. 1A trail complete in GBM ✓ Ph. 1A Positive Preliminary Data in GBM ✓ Ph. 1B 1st Patient Treated in GBM	• Ph. 1B new trial design
CHM CORE-NK CHM 0201	✓ Ph. 1B ADVENT AML Site Initiation ✓ Ph. 1B CORE-NK 0201 + Vactosertib 1st Patient Treated	✓ Ph. 1B ADVENT AML 1st Patient Treated • Ph. 1B ADVENT AML Dose Escalation • Ph. 1B ADVENT AML Preliminary Data

CHIMERIC THERAPEUTICS

20
24

INVESTMENT HIGHLIGHTS

- **4 phase 1/1b clinical trials**
  under 3 FDA INDs at 4 leading US centres
- **Multiple clinical updates**
  in the next 12mths
- **Experienced leadership team**
  in cell therapy clinical development
- CHM-CDH17
  the ONLY CDH17 CAR-T in clinical trials
- **First in class**
  CLTX-CAR for brain cancer
- **Robust and long life**
  patent portfolio

CORPORATE PROFILE

Exchange	**ASX:CHM**
Share Price	**$0.02**
52 Week Range	**$0.018- 0.047**
Market Cap	**~$16M**
Shares on issue	**841M**

IPO 2022

Capital Raised since IPO	**$69M**
Major Shareholder: Paul Hopper	**11.1%**

CHIMERIC THERAPEUTICS

APPENDIX

CHM LEADERSHIP TEAM

EXPERTS IN CELL THERAPY DEVELOPMENT & COMMERCIALISATION

Dr Rebecca McQUALTER
Chief Operating Officer

Dr Jason LITTEN
Chief Medical Officer

Dr Stephanie ASTROW
VP Translational Sciences

Kelly THORNBURG
VP Manufacturing

EXPERIENCE **75+** Years of Cell Therapy Experience

EXPERTISE **50+** Development Programs

RESULTS **5/6** FDA-Approved CAR T Cell Therapies

juno AMGEN Celgene Kite YESCARTA TECARTUS

NOVARTIS Fate artiva Breyanzi KYMRIAH Abecma

WHAT IS CELL THERAPY?

Cell therapy is the transfer of live cells into a patient to help lessen or cure a disease. In its most basic form is a blood transfusion.

Today's cell therapies can involve the engineering of live cells to attack specific diseases



Genes programmed with the information needed to make special receptors called "Chimeric Antigen Receptors" (CARs) are inserted into live cells.



The Chimeric Antigen Receptors (CARs) become expressed on the cell surface and are activated to search for specific cancer cells.



Once the Chimeric Antigen Receptor (CAR) finds the specific cancer cell it was programmed to find, it attaches itself to the cancer cell and sends a signal to kill it.

WHAT IS CELL THERAPY?

ALTERNATIVE CELL TYPES: T CELLS VS. NK CELLS

T CELLS

T cells are part of the adaptive immune system- primed to recognise a specific threat on a foreign cell surface

- Proven curative efficacy in blood cancers
- Primed to target and attack specific antigens
- Direct killing of cancer cells

NK CELLS

Natural Killer (NK) cells are part of the innate immune response – responding to anything that appears to be non-self

- Intrinsic ability to identify and kill cancer cells
- Direct and indirect killing of cancer cells
- Low risk of safety concerns

CHIMERIC THERAPEUTICS

CHM CDH17 CAR T

PHASE 1/2 CLINICAL TRIAL IN GI CANCERS

OBJECTIVES:
Characterise the safety and tolerability of CDH17 CAR and determine the recommended Phase 2 dose (RP2D) for Phase 2

PRIMARY ENDPOINTS:
- DLT's, Safety Profile
- AE's, CRS, ICANS

SECONDARY ENDPOINTS:
- ORR, DCR, TTR, DOR,
- PFS, OS
- Cellular Kinetics

COLORECTAL CANCER

NETs
G1, G2, and well-differentiated G3 NETs of the midgut and hindgut with ≤ 55% Ki67 expression

GASTRIC CANCER
Central laboratory confirmation of CDH17+ tumor expression by IHC (H score ≥ 5) is required.



DOSE ESCALATION

Tumor Specific Dose Confirmation

Tumor Specific Dose Expansion

Upon signal confirmation, dose confirmation and expansion in tumour specific cohorts

CHM CDH17
CHM 2101

Penn
University of Pennsylvania

CHM CDH17 CAR T

TARGET COMPETITORS IN DETAIL

	Preclinical		Phase 1	
Cell Therapy	**CDH17 CAR T** Ospedale San Raffaele	**CHM CDH17** CDH17 CAR NK Chimeric Therapeutics	**CHM CDH17** CDH17 CAR T Chimeric Therapeutics	
	ARB011 CDH17 NK/T Arbele Bio	**ARB001** CDH17 CAR T Arbele Bio		
	CDH17 CAR T +IL7/21 Eastern Theater General Hospital of PLA			
Non-Cell Therapy	**CDH17 x pCAD ADC** Novartis	**AMT-676** CDH17 ADC Multitude Therapeutics	**TORL-3-600** CDH17 ADC TORL Biotherapeutics	**Cabotamig (ARB202)** CDH17 ADC Arbele Bio
	CDH17 A4 CDH17 mAb Oxford Biotherapeutics	**ARB101a** CDH17 ADC Arbele Bio	**BI 905711** CDH17xTRAILR2 bsAb Boehringer Ingelheim	

Updated 03Jul24

Legend

Chimeric programs | T cell therapies | NK or NK/T therapies | Australian biotech

CHM CDH17
CHM 2101

Penn
University of Pennsylvania

CHIMERIC THERAPEUTICS

CHM CLTX CAR T

ADVANCING DEVELOPMENT TO PHASE 1B

CLINICAL TRIALS.GOV IDENTIFIER: **NCT05627323**

OBJECTIVES:

- PFS, OS, ORR
- Safety & Feasibility
- RP2D
- Cellular Kinetics

PATIENT POPULATION:

- Recurrent / progressive glioblastoma

PART A
DOSE CONFIRMATION

440×10^6

3-6 PATIENTS

SAFETY & EFFICACY ASSESSMENT

PART B
DOSE EXPANSION

440×10^6

12-26 PATIENTS

CHM CLTX
CHM 1101

City of Hope

CHIMERIC THERAPEUTICS

POSITIVE PRELIMINARY PHASE 1A CLINICAL DATA IN BRAIN CANCER (GLIOBLASTOMA)

DISEASE CONTROL RATE

55%

Disease Control Rate (DCR) in heavily pretreated patients

Exceeding historical disease control rates of 20-37%[1]

SURVIVAL

~10 months

Median survival in patients that achieved disease control

14+ months

Survival in two patients that achieved disease control

~7 month survival expectation after first recurrence[2]

CHM CLTX

CHM 1101

City of Hope

CHIMERIC THERAPEUTICS

CHM CLTX PHASE 1B IMPROVED DESIGN

PROPOSED CLINICAL DESIGN: ADDITION OF SYSTEMIC DELIVERY AND CHEMOTHERAPY

CLINICAL TRIALS.GOV IDENTIFIER: **NCT05627323**



CHM CLTX
CHM 1101

City of Hope

20 24

CHIMERIC THERAPEUTICS

ADVENT-AML PHASE 1B CLINICAL TRIAL

CHM CORE-NK 0201 + AZA + VEN IN FRONT-LINE AML

HIGH UNMET NEED IN AML

Despite treatment advances, outcomes for AML patients not eligible for intensive chemotherapy or allogeneic stem cell transplant are poor

CHM CORE-NK 0201 + AZACITIDINE + VENETOCLAX

A Phase Ib Trial of Azacitidine, Venetoclax and CHM CORE-NK 0201 Allogeneic NK Cells for Acute Myeloid Leukemia

Study Initiation:	Q1, 2024
Enrolment:	23 participants
Dose Escalation Eligibility:	Relapse or refractory AML, or MDS/AML with 10% to 19% blasts
Dose Expansion Eligibility:	Newly diagnosed, older/unfit patients with adverse risk AML or MDS/AML
Clinical Trials.gov Identifier:	**NCT05834244**

CHM CORE-NK
CHM 0201

CASE WESTERN RESERVE UNIVERSITY

2024

CHIMERIC THERAPEUTICS

CHM CORE-NK 0201 + VACTOSERTIB

FDA APPROVED FIRST EVER TRIAL OF NK CELLS WITH VACTOSERTIB

A Phase Ib Study to Evaluate Safety and Persistence of ex Vivo Expanded Universal Donor NK Cells in Combination With IL-2 and TGF-beta Receptor I Inhibitor Vactosertib

Study Initiation: Jan 2023 (paused due to staff issue)
Enrolment: 12 Patients
Est. Completion: Late 2024

Eligible Patients: Relapse or refractory solid tumours and haematological malignancies

Clinical Trials.gov Identifier: **NCT05400122**

CHM CORE-NK
CHM 0201

CASE WESTERN RESERVE UNIVERSITY

CHM CORE-NK DEVELOPMENT PLAN

THE FUTURE

1

CHM 0201 COMBINATIONS

Exploring novel combinations utilising NK cells with standard of care therapies

2

CHM 0301 NEXT GENERATION PLATFORM

Next generation armoured platform development

3

CAR-NK PRODUCTS

Development of CAR NK products utilising our CLTX and CDH17 chimeric antigen receptors

CHM CORE-NK

CHM 0201

CASE WESTERN RESERVE UNIVERSITY

CHIMERIC THERAPEUTICS

CHIMERIC

PIONEERS IN CELL THERAPY

Dr Rebecca McQualter
Chief Operating Officer
Chimeric Therapeutics Ltd
Melbourne, Australia
Tel: +61 498 966 180
investor@chimerictherapeutics.com

ASX:
CHM

20
24